Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.~2. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.~3. The sick child has to be over 2 years old or a head circumference big enough for surgery.~4. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.~5. Parents or guardians must sign to agree on this informed consent.~Exclusion criteria~1. Significant brain structure abnormality~2. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.~3. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.~4. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gene therapy (Type: EXPERIMENTAL): Intracerebral infusion of AAV2-hAADC viral vector will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).